{"filings":[{"id":1580438,"accession_number":"0001213900-26-077127","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-07-10T20:02:00+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"InMed amends merger with Mentari; files S-4; clarifies name change, redomestication, tax treatment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment clarifies sequencing: InMed will change name to Mentari Therapeutics and redomesticate to Nevada before closing.","Amendment introduces Company PIPE Amendment concept to facilitate additional pre-closing financing and clarifies impact on exchange ratio.","Tax treatment clarified: First and Second Mergers intended to qualify as a reorganization under Section 368(a) of the IRC.","Merger expected to close in Q4 2026, subject to shareholder approvals, S-4 effectiveness, and other conditions.","InMed filed Form S-4 on July 2, 2026, containing preliminary proxy statement/prospectus and management information circular."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":954198,"accession_number":"0001062993-26-003132","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-06-10T10:01:19+00:00","items":["8.01","9.01"],"status":"ready","headline":"InMed regains Nasdaq minimum bid price compliance; deficiency closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 3, 2026 that bid price was at or above $1.00 for 10 consecutive business days (May 19–June 2).","Previously notified of deficiency on March 27, 2026 for bid price below $1.00 for 30 consecutive days.","Nasdaq has closed the matter; Company remains listed on the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":513159,"accession_number":"0001213900-26-058795","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-05-19T14:32:30+00:00","items":["1.01","5.01","5.02","7.01","9.01"],"status":"ready","headline":"InMed to merge with Mentari; pre-Merger InMed holders to own ~1.51% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger: InMed shareholders to own ~1.51% of combined entity; Mentari stockholders ~98.49%.","Concurrent $290M private placement led by Fairmount; funds operations through 2028.","Mentari's lead programs: MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) targeting migraine prevention.","Pre-Merger InMed shareholders receive Contingent Value Rights (CVRs) for net proceeds from legacy asset sales.","Closing conditions include $150M+ pre-closing financing, shareholder approvals, and Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":507958,"accession_number":"0001062993-26-002787","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-05-19T10:03:08+00:00","items":["1.01","3.03","8.01","9.01"],"status":"ready","headline":"InMed amends Armistice option exercise price from $16.60 to $0.80 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to 278,761 common shares subject to options; exercise price reduced to $0.80 from $16.60.","Options originally issued October 26, 2023; amendment entered May 18, 2026.","Dramatic price reduction may increase dilution risk for existing shareholders if exercised.","Press release issued May 19, 2026 confirms amendment; no assurance options will be exercised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95041,"accession_number":"0001062993-26-002371","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed Q3 net loss $3.0M; INM-901 Alzheimer's data positive, BayMedica exit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $2.8M (Q3 FY2026) vs $2.1M prior year; total net loss $3.0M.","R&D spending rose to $1.0M from $0.4M, driven by INM-901 Alzheimer's program costs.","Cash and equivalents decreased to $5.2M as of March 31, 2026 from $10.8M at June 30, 2025.","INM-901 showed anti-neuroinflammatory effects in human 3D brain organoid models of Alzheimer's disease.","Board approved wind down of BayMedica commercial operations, expected completion by June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95040,"accession_number":"0001213900-26-048064","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["1.01","3.03","8.01","9.01"],"status":"ready","headline":"InMed reduces exercise price of Sabby and Wainwright preferred investment options to $0.80","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sabby options now exercisable at $0.80 (was $2.436) for up to 2,151,478 shares.","Wainwright options exercise price reduced to $0.80 from $82.50, $20.75, and $3.2013 for 153,236 shares.","Amendments signed April 21 and April 24, 2026; announced April 27.","Lower exercise price could lead to exercise and dilution of existing shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95039,"accession_number":"0001213900-26-039943","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"InMed files prospectus supplement for ATM offering of common shares under existing Sales Agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement dated April 3, 2026 for at-the-market equity offering.","ATM facility is under Sales Agreement with H.C. Wainwright & Co., originally dated April 7, 2022, amended June 27, 2024.","Shelf registration statement on Form S-3 (File No. 333-294503) declared effective March 30, 2026.","No specific number of shares or dollar amount disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107829,"accession_number":"0001062993-26-001697","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"InMed receives Nasdaq notice of bid price deficiency; 180 days to cure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on March 27, 2026; closing bid price below $1.00 for 30 consecutive days (Feb 11–Mar 26).","Must achieve $1.00 or more for 10 consecutive business days within 180 calendar days to regain compliance.","If not cured, may qualify for additional 180-day period, subject to other listing standards and possible reverse split.","No immediate effect on listing; shares continue trading on Nasdaq under symbol INM.","Company monitoring share price and exploring options, including reverse stock split if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107828,"accession_number":"0001062993-26-001567","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed reports positive INM-901 data in human brain organoid neuroinflammation models","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["INM-901 reduced neuroinflammation in 3D human brain organoid models of Alzheimer's disease.","Dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8 observed in two distinct organoid models.","Company targets pre-IND meeting with FDA in Q3 2026 and Phase 1 trial start in 2027.","Prior studies showed reduction of inflammatory biomarkers in in vivo Alzheimer's and ex vivo LPS models.","Studies conducted with Stem Pharm's proprietary neuro-immune organoid platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107827,"accession_number":"0001062993-26-001347","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed provides 2026 pipeline outlook; pre-IND meetings targeted for INM-901 and INM-089","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical data for INM-901 shows reduced neuroinflammatory biomarkers, neuroprotection, and behavioral improvements in Alzheimer's models.","Targeting pre-IND meeting with FDA for INM-901 in Q3 2026 and for INM-089 in Q4 2026.","INM-901 aims for IND submission and Phase 1 clinical trial initiation in 2027.","INM-089 (dry AMD) completed dose-ranging studies; drug substance process in place for IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107826,"accession_number":"0001213900-26-024752","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"InMed to wind down BayMedica commercial ops; focus shifts to Alzheimer's, AMD pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board ratified wind-down of BayMedica commercial operations due to H.R. 5371 uncertainty; completion expected by June 30, 2026.","Estimated severance costs of ~$550K and other expenses ~$120K; partially offset by product sale profits during wind-down.","Company will focus exclusively on INM-901 (Alzheimer's) and INM-089 (dry AMD) drug candidates; commercial revenue stream eliminated.","Pro forma financial statements treat BayMedica as discontinued operations; revenue from commercial ops reduced to $0."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107825,"accession_number":"0001062993-26-000819","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed Q2 FY2026 net loss $2.03M; cash drops to $7.0M; warns of material impact from pending US legislation on BayMedica","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.03M for Q2 FY2026 (EPS -$0.51) vs net loss $2.58M in prior year; gross profit fell to $184K from $461K.","Cash and equivalents $7.0M at Dec 31, 2025 vs $11.1M at June 30, 2025; expects runway into Q4 calendar 2026.","BayMedica revenues $0.8M, down 26% YoY, due to pending US legislation H.R. 5371 that may prohibit certain cannabinoid sales after Nov 12, 2026.","INM-901 Alzheimer's candidate advanced: oral formulation showed robust bioavailability in large animal PK study; no adverse neural effects.","R&D expenses fell to $0.6M from $0.9M; expects substantial increase in H2 FY2026 for IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":1940309.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124226,"accession_number":"0001062993-25-017390","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"InMed shareholders re-elect all five directors, approve auditor and share issuance at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with 81.9% to 82.1% support.","Appointment of CBIZ CPAs P.C. as auditor for 2026 approved (78.8% for).","Shareholders approved potential issuance of >=20% of shares under SEPA with YA II PN (65.9% for).","Turnout was 993,491 shares (35.43% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124225,"accession_number":"0001213900-25-121497","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"New US law to materially hurt InMed's BayMedica cannabinoid business; core pharma programs unaffected","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["H.R. 5371, signed into law, will prohibit BayMedica's commercial inventory of rare, non-intoxicating cannabinoids as of Nov 12, 2026, in its current form.","BayMedica is evaluating alternative supply chain options to maintain regulatory compliance.","InMed's pharmaceutical programs (INM-901 for Alzheimer's, INM-089 for AMD) are not affected by the legislation.","Company warns of material negative impact on BayMedica's contribution to consolidated financial results.","Act may be amended before Nov 12, 2026, but current form already enacted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124224,"accession_number":"0001213900-25-112644","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed announces positive PK data for Alzheimer's candidate INM-901 in large animal model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral formulation of INM-901 showed robust bioavailability over 7-day dosing in large animals.","Neurological assessments found no adverse effects on attitude, behavior, or motor function.","Company preparing for pre-IND meeting with FDA; advancing CMC scale-up and dose-ranging studies.","Data support design of first-in-human Phase 1 clinical trial for INM-901."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124223,"accession_number":"0001213900-25-099529","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"InMed appoints John Bathery to board; director Baldasare to depart at AGM","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Bathery appointed to Board effective Oct 14, 2025; Board expands to six members.","Bathery has 30+ years pharma experience, currently Head of Global BD at Takeda, led deals exceeding $60B.","Bryan Baldasare will not stand for re-election at 2025 AGM due to increasing professional obligations; no disagreements.","Bathery's expertise expected to support INM-901 (Alzheimer's) and INM-089 (AMD) programs toward clinical readiness and partnerships.","Bathery receives standard non-employee director compensation: $50,000 annual retainer, potential committee fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124222,"accession_number":"0001213900-25-098229","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"InMed announces Dec 17, 2025 annual meeting; record date Oct 22, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual general and special meeting set for December 17, 2025.","Record date for notice and voting is October 22, 2025.","Meeting will consider matters typical for annual meetings; no specific proposals detailed.","Company filed notice via SEDAR; proxy materials to be sent using notice and access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124221,"accession_number":"0001213900-25-098205","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"InMed appoints Neil Klompas to board, effective October 9, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neil Klompas, CPA, CA, appointed to Board; board size increased to 5 members.","Klompas brings 30+ years experience; was President/COO and CFO at Zymeworks (NASDAQ: ZYME), led 2017 IPO.","Currently CEO of Augerex Life Science Corp, serves on boards of NervGen Pharma (TSXV: NGEN) and HTuO Biosciences.","He will receive standard non-employee director compensation: US$50k annual retainer plus potential committee fees.","No related party transactions or family relationships with any director or officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140895,"accession_number":"0001213900-25-090715","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed reports FY2025 net loss of $8.2M; BayMedica revenue up 8% to $4.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.2M vs $7.7M prior year; diluted EPS ($8.36) vs ($20.14) on higher share count.","Cash $11.1M, up from $6.6M; expected to fund operations into Q4 2026.","BayMedica segment sales $4.9M (+8% YoY); gross profit rose to $1.7M from $1.1M.","INM-901 Alzheimer's candidate: significant neuroinflammation reductions and oral bioavailability data.","INM-089 dry AMD program selected intravitreal formulation; doses up to 10x safety margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140894,"accession_number":"0001213900-25-090695","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"InMed sets Dec 17, 2025 annual meeting; record date Oct 22, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual General Meeting on December 17, 2025.","Record date for notice and voting: October 22, 2025.","Securities entitled to vote: Common Shares (ISIN CA4576377002).","Notice and Access method will be used for both beneficial and registered holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140893,"accession_number":"0001213900-25-085213","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed to participate in H.C. Wainwright 27th Annual Global Investment Conference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Conference takes place September 8-10, 2025 in New York.","Management will conduct one-on-one investor meetings and a corporate presentation is available online.","COO Michael Woudenberg will highlight pipeline updates including INM-901 Alzheimer's program data from AAIC 2025.","No new financial or operational results disclosed; presentation is for investor outreach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140892,"accession_number":"0001213900-25-068190","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed to present INM-901 preclinical data at AAIC 2025; long-term study shows multi-modal activity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical data from INM-901 program presented at Alzheimer's Association International Conference (AAIC) 2025 in Toronto.","Long-term study in 5xFAD mouse model with advanced disease; treatment duration longer than previous studies.","INM-901 reduced inflammatory biomarkers IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, NfL in dose-dependent manner.","Immunohistochemistry showed dose-dependent reduction in amyloid-beta immunoreactivity and partial restoration of MAP2.","Behavioral improvements: cognitive function, anxiety-related behavior, sensory responsiveness restored or approaching normal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158651,"accession_number":"0001213900-25-059673","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"InMed Pharma raises $5M in private placement of pre-funded warrants and options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5M from 1,952,363 pre-funded warrants ($0.0001 exercise) and 1,952,363 preferred investment options at $2.436/share.","Amended 199,115 existing options (Oct 2023) from $16.60 to $2.436 per share for $0.125 each.","Proceeds to fund pipeline development, BayMedica commercial sales, and working capital.","H.C. Wainwright acted as placement agent; received 126,904 agent options at $3.2013/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158650,"accession_number":"0001213900-25-057139","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed's INM-901 reduces neuroinflammation markers in Alzheimer's ex vivo study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["INM-901 statistically significantly reduced pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro in LPS-induced ex vivo model.","INM-901 significantly reduced inflammasome marker NLRP3, a key contributor to neurodegeneration.","Reduction of pro-inflammatory markers independent of amyloid beta or tau pathology.","Company plans to advance INM-901 through additional preclinical studies with IND-enabling studies to follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158649,"accession_number":"0001213900-25-054315","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.01","4.01","5.07","9.01"],"status":"ready","headline":"InMed special meeting lacks quorum for share issuance vote; appoints new auditor CBIZ","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on June 13, 2025 lacked quorum; ~60% of voted shares favored share issuance proposal but no vote held. Board evaluating next steps.","Marcum resigned as auditor after acquisition by CBIZ; Board appointed CBIZ as independent auditor for FY2025. No disagreements; prior material weakness remediated.","Company amended SEPA with Yorkville to allow suspension of registration statement during black-out periods, subject to restrictions similar to insider trading policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158648,"accession_number":"0001213900-25-042251","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed Q3 FY2025 net loss $2.12M, revenue $1.26M, cash $4.68M, needs financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.12M for Q3 ended Mar 31, 2025, vs $1.72M same quarter last year; loss per share $1.94.","BayMedica revenue $1.26M (+8% YoY); gross margin declined due to pricing pressure.","Cash and equivalents $4.68M (Jun 30, 2024: $6.57M); expects to fund operations into Q3 2025.","R&D expenses $0.91M vs $0.65M YoY, driven by INM-901 and INM-089 programs.","Company seeks additional financing through equity, debt, or collaborations to fund pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":3637923.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158647,"accession_number":"0001213900-25-035646","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"InMed cancels prior special meeting notice; new meeting set for June 13, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Odyssey Trust Company filed amended notice to cancel prior special meeting date and record date.","New special meeting of shareholders scheduled for June 13, 2025.","Record date for notice and voting set as April 29, 2025.","Meeting type: Special Meeting; common shares entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158646,"accession_number":"0001213900-25-029501","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"InMed schedules special shareholder meeting for June 13, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting set for June 13, 2025; record dates for notice and voting both April 29, 2025.","Meeting purpose not disclosed in the filing; shareholders await proxy materials for agenda.","Notice filed via SEDAR in Canada; proxy materials will be sent using notice-and-access.","Securities entitled to vote: Common Shares (ISIN CA4576377002)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177046,"accession_number":"0001213900-25-014154","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"InMed reports Q2 net loss $2.6M, cash $3.5M; board accepts director resignation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.6M for Q2 FY2025 (Dec 31, 2024), vs $1.5M loss a year ago; GAAP loss per share $3.64.","Cash and equivalents $3.5M as of Dec 31, 2024; company raised $2.9M in Jan 2025, enough through Q2 2025.","BayMedica revenue $1.1M (-10% YoY); BayMedica achieved net income of $0.23M (189% improvement).","Board accepted resignation of director Janet Grove effective Feb 10, 2025, following withheld votes at Dec 2024 AGM.","R&D expenses $1M (up from $0.6M); pipeline updates: INM-901 (Alzheimer's) and INM-089 (dry AMD)."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":2376345.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177045,"accession_number":"0001213900-25-013204","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed Q2 net loss $2.6M, cash burn continues; BayMedica profitable amid revenue drop","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $2.6M vs $1.5M YoY; BayMedica revenue $1.1M (-10% YoY).","Cash $3.5M at Dec 31, 2024; raised $2.9M in Jan 2025; expects funding through Q2 2025.","INM-901 Alzheimer's preclinical data reduced neuroinflammatory markers; INM-089 IVT formulation for dry AMD.","Director Janet Grove resigned after withheld votes at Dec 2024 AGM; board to find replacement.","BayMedica net income $0.23M (+189%) despite revenue drop due to cost cuts."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":2376345.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177044,"accession_number":"0001213900-25-009213","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed selects IVT formulation for INM-089 in dry AMD; preclinical data shows 10x safety margin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selected intravitreal (IVT) formulation for INM-089 as drug candidate for dry age-related macular degeneration (AMD).","Preclinical studies demonstrated successful delivery at doses up to 10 times projected therapeutic level, indicating favorable PK and safety margin.","Completed dose-ranging in vivo studies to guide dose selection for pivotal preclinical toxicology studies.","Intravitreal injection is established method for drug delivery to back of eye; overcomes challenges of topical formulations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177043,"accession_number":"0001213900-25-005263","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed granted first PCT patent in Mexico for novel cannabinoid analog compounds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patent No. 417531 issued in Mexico; covers novel small molecule compounds and methods of preparation.","Therapeutic applications include pain, glaucoma, inflammatory disease, anxiety, and neurological conditions like Parkinson's and Alzheimer's.","Patent holds 20-year term; international application pending in U.S., Europe, Japan, and others.","InMed now has 14 patent families covering compositions, formulations, manufacturing, and methods of use.","Compounds are drug candidates for Alzheimer's disease and dry age-related macular degeneration programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177042,"accession_number":"0001213900-25-004873","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INM-901 shows statistically significant reduction in neuroinflammation in long-term Alzheimer's model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["INM-901 dose-dependently and significantly reduced pro-inflammatory cytokines TNF-α, IL-1β, and INF-γ.","High dose group showed statistically significant reduction in neurodegeneration biomarker NfL in plasma.","mRNA data showed reduction of neuroinflammatory genes GFAP, CD-33, TLR-2 in brain, supporting study results.","Company will complete analyses of receptor engagement, neuritogenesis, and neuroprotection in coming weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193826,"accession_number":"0001213900-24-110429","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"InMed director Janet Grove fails re-election; resignation tendered per majority voting policy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Janet Grove received only 44.26% votes for (55.74% withheld); per policy she tendered resignation to Board chair.","Nominating & Governance Committee will review whether to accept Grove's resignation; update to follow.","Four other director nominees re-elected with >96% votes for each (Adams, Hull, Lemerond, Baldasare).","Shareholders approved appointment of Marcum LLP (now CBIZ LLP) as independent auditor for the next year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193825,"accession_number":"0001213900-24-109891","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"InMed enters $10M standby equity facility with Yorkville; shares at 97% of VWAP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $10M common shares may be sold to YA II PN, Ltd (Yorkville) at 97% of lowest daily VWAP over 3-day pricing period.","Facility runs until Jan 1, 2027 (~36 months); issuance capped at 19.99% of outstanding (unless pricing conditions met).","Company pays $25k structuring fee plus 2.50% commitment fee ($250k) – 25% cash upfront, 75% deferred quarterly.","Proceeds for working capital and general corporate purposes; CEO cites flexibility and extended runway.","Sales at company's discretion; no obligation to sell any shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193824,"accession_number":"0001213900-24-100527","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed publishes study on cannabinol anti-inflammatory effects in skin diseases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study published in peer-reviewed journal Biofactors; sponsored by InMed and led by Dr. Maccarrone.","CBN prevented keratinocyte inflammation via TRPV1 and modulated endocannabinoid system enzymes.","CBN reduced pro-inflammatory cytokines (IL-8, IL-12, IL-31) and increased anti-inflammatory IL-10.","Potential applications for psoriasis, atopic dermatitis, and pruritus; supports cosmetic and therapeutic use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193823,"accession_number":"0001213900-24-098655","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed Q1 FY2025 revenue $1.3M (+40% YoY); net loss narrows to $1.68M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["BayMedica revenue $1.3M, up 40% YoY; BayMedica generated $0.3M net income (24% margin).","Net loss narrowed to $1.68M ($2.17/sh) from $2.54M ($15.24/sh) in Q1 FY2024.","Cash and equivalents $5.6M at Sep 30, 2024, down from $6.6M at June 30, 2024; expects cash to fund through Q1 calendar 2025.","Reverse stock split effective Nov 14, 2024 to regain Nasdaq minimum bid price compliance.","Preclinical data for Alzheimer's candidate INM-901 shows oral bioavailability and significant behavioral results; data expected Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":1264638.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193822,"accession_number":"0001213900-24-096025","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["3.03","7.01","8.01","9.01"],"status":"ready","headline":"InMed announces 1-for-20 reverse share split to regain Nasdaq $1 bid compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Consolidation ratio 1:20 reduces shares from ~14.36M to ~718k on a non-diluted basis.","Effective with Nasdaq on Nov 14, 2024; adjusted trading begins Nov 15, symbol INM unchanged.","No fractional shares issued; fractions under 0.5 cancelled, otherwise rounded up.","Proportionate adjustment to exercise prices and share counts of options/warrants/convertibles.","Action taken to meet Nasdaq minimum $1.00 bid price continued listing requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193821,"accession_number":"0001213900-24-094349","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"InMed Pharmaceuticals granted Nasdaq exception until Dec 2; plans 1-for-20 reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Panel grants InMed exception to Dec 2, 2024 to show $1 bid price compliance for 10 consecutive trading days.","Board approved 1-for-20 reverse stock split on Oct 29, 2024; shares would reduce from ~14.36M to ~718k.","Reverse split requires no shareholder action; fractional shares not issued; trading symbol INM unchanged.","Company must evidence compliance by Dec 2; no assurance of regaining compliance by that date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193820,"accession_number":"0001213900-24-091172","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed files PCT patent application for INM-901 treating Alzheimer's and neurodegeneration","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["PCT patent covers composition, method of use for INM-901 in neurodegenerative diseases including Alzheimer's.","Patent claims neuroprotection, neurite elongation, cognitive/memory improvement, and anti-inflammatory effects.","InMed now has 14 patent families; eight on drug composition/formulations, six on manufacturing technologies.","Company plans to present long-term in vivo data for INM-901 in coming weeks.","INM-901 is an oral small molecule with CB1/CB2 and PPAR activity, targeting multiple Alzheimer's pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193819,"accession_number":"0001213900-24-090365","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed to participate in Fierce Biotech webinar on Alzheimer's neuroinflammation on Nov 12, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["InMed (Nasdaq: INM) announced participation in Fierce Biotech webinar on November 12, 2024.","SVP of Preclinical R&D Dr. Eric Hsu will join a panel on neuroinflammation in Alzheimer's disease.","Webinar topics include latest Alzheimer's research, therapeutic pathways, and drugs in development.","Panel includes experts from Eli Lilly, Johns Hopkins, Michigan State, and Barrow Neurological Institute.","No financial results or material business changes were disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193818,"accession_number":"0001213900-24-089887","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed adds Johns Hopkins Alzheimer's expert Dr. Barry Greenberg to Scientific Advisory Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Greenberg is Director of Alzheimer's Disease Translational Center at Johns Hopkins University School of Medicine.","He has over four decades of Alzheimer's research and held leadership roles at AstraZeneca and Neurochem.","His expertise will guide InMed's INM-901 drug candidate toward human clinical trials for Alzheimer's disease.","He serves as Editor-in-Chief of 'Alzheimer's & Dementia: Translational Research and Clinical Interventions'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210158,"accession_number":"0001213900-24-083203","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed FY2024 net loss $7.7M; revenue up 11% to $4.6M; cash $6.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.7M vs $7.9M prior year; diluted EPS loss $1.01 vs $3.25.","Revenue from BayMedica segment $4.6M, up 11% YoY; gross profit $1.1M.","Cash, equivalents, and short-term investments $6.6M at June 30, 2024.","R&D and patent expenses $3.8M; G&A $5.3M, down from $5.8M.","Pipeline update: INM-901 Alzheimer's program advancing; INM-089 dry AMD preclinical data positive."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":1264638.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210157,"accession_number":"0001213900-24-082247","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"InMed sets 2024 annual meeting for Dec 18; record date Oct 21","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual general meeting scheduled for December 18, 2024.","Record date for notice and voting is October 21, 2024.","Meeting will be held for common shareholders (ISIN CA4576376012).","Issuer uses notice-and-access for both beneficial and registered holders.","Odyssey Trust Company acts as agent for the issuer in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210156,"accession_number":"0001213900-24-080662","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"InMed receives Nasdaq delisting notice for bid price non-compliance; hearing set for Oct 31, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff issued delisting notice on Sept 17, 2024, after company failed to meet minimum $1.00 bid price by Sept 16, 2024 compliance deadline.","Company timely filed an appeal; hearing before Nasdaq Listing Qualifications Panel scheduled for October 31, 2024.","Appeal stays delisting pending panel decision; panel may grant up to 180 additional calendar days to regain compliance.","No guarantee extension will be granted or that outcome will be favorable; shares risk suspension or delisting.","Previously received 180-day extension on March 19, 2024 to cure deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210155,"accession_number":"0001213900-24-071386","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed Pharma issued 3 US patents for EB treatment, biosynthesis, ocular delivery","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patent for INM-755 cannabinoid topical for epidermolysis bullosa granted in US, Australia, Japan, Israel.","Biosynthesis patent for manufacturing proprietary analogs granted in US, issued Sept 3, 2024.","Ocular drug delivery formulation patent granted/allowed in US, Europe, Australia, Japan, India.","Total IP portfolio now 13 patent families covering NCEs, formulations, manufacturing, methods of use.","Company continues pursuing patent protection for INM-901 (Alzheimer's) and INM-089 (dry AMD)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210154,"accession_number":"0001213900-24-071061","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed confirms INM-901 oral formulation for Alzheimer's; bioavailability comparable to injection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical data show oral INM-901 achieves similar brain drug levels as intraperitoneal (IP) injection over 24h.","Oral delivery offers potential advantages over IV large-molecule antibody therapies, including lower cost and easier access.","INM-901 is a proprietary small molecule that crosses the blood-brain barrier via GI absorption.","Company conducting CMC, drug metabolism, dose-ranging, and PK studies to support IND submission.","Current disease-modifying Alzheimer's treatments require IV infusion every 2-4 weeks at medical facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210153,"accession_number":"0001013762-24-002578","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed reports positive long-term preclinical AD study results for INM-901 confirming prior pilot data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Long-term (7-month) in vivo study confirms cognitive and memory improvements seen in 3-month pilot using 5xFAD amyloidosis model.","INM-901-treated AD groups achieved statistical significance in certain behavioral assessments vs. placebo.","Clear dose response observed across Novel Object Recognition, Open Field, Barnes Maze, and other tests.","Additional molecular analyses (receptor engagement, neuroinflammation, neurogenesis, neuroprotection) are ongoing.","CMC/GLP studies being planned to support IND submission; INM-901 targets CB1/CB2/PPAR pathways and penetrates BBB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228409,"accession_number":"0001213900-24-056807","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"InMed amends ATM equity offering agreement with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to April 2022 at-the-market offering agreement with H.C. Wainwright & Co.","Settlement cycle updated to T+1 (first trading day) to reflect current market rules.","New data privacy compliance representation added; $50k cap on agent's counsel fees reimbursed.","Company to file a prospectus supplement and deliver customary closing deliverables on June 27, 2024.","Prior letter agreements from October 2023 and June 2024 remain effective unless conflicting with amended ATM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228408,"accession_number":"0001213900-24-051625","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed to present at Emerging Growth Conference on June 13, 2024","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Eric A. Adams will present a corporate overview at the Emerging Growth Conference 72.","Presentation scheduled for 1:45pm EDT on June 13, 2024; registration link provided.","Archived webcast available on EmergingGrowth.com, YouTube channel, or InMed IR page."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5368782.469879518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-06-11T23:59:59+00:00|228408"}